These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 17149882)
1. Design and evaluation of hydroxamate derivatives as metal-mediated inhibitors of a protein tyrosine kinase. Gu X; Wang Y; Kumar A; Ye G; Parang K; Sun G J Med Chem; 2006 Dec; 49(25):7532-9. PubMed ID: 17149882 [TBL] [Abstract][Full Text] [Related]
2. Substitution studies of the second divalent metal cation requirement of protein tyrosine kinase CSK. Sun G; Budde RJ Biochemistry; 1999 Apr; 38(17):5659-65. PubMed ID: 10220355 [TBL] [Abstract][Full Text] [Related]
3. Affinity purification of Csk protein tyrosine kinase based on its catalytic requirement for divalent metal cations. Sun G; Budde RJ Protein Expr Purif; 2001 Feb; 21(1):8-12. PubMed ID: 11162381 [TBL] [Abstract][Full Text] [Related]
4. Benzodiazepine compounds as inhibitors of the src protein tyrosine kinase: screening of a combinatorial library of 1,4-benzodiazepines. Ramdas L; Bunnin BA; Plunkett MJ; Sun G; Ellman J; Gallick G; Budde RJ Arch Biochem Biophys; 1999 Aug; 368(2):394-400. PubMed ID: 10441393 [TBL] [Abstract][Full Text] [Related]
5. ATP-phosphopeptide conjugates as inhibitors of Src tyrosine kinases. Nam NH; Lee S; Ye G; Sun G; Parang K Bioorg Med Chem; 2004 Nov; 12(22):5753-66. PubMed ID: 15498652 [TBL] [Abstract][Full Text] [Related]
6. Synthesis and pharmacological evaluation of novel beta-nitrostyrene derivatives as tyrosine kinase inhibitors with potent antiplatelet activity. Wang WY; Hsieh PW; Wu YC; Wu CC Biochem Pharmacol; 2007 Aug; 74(4):601-11. PubMed ID: 17601492 [TBL] [Abstract][Full Text] [Related]
7. Inhibition and structure-activity studies of methionine hydroxamic acid derivatives with bacterial peptide deformylase. Grant SK; Green BG; Kozarich JW Bioorg Chem; 2001 Aug; 29(4):211-22. PubMed ID: 16256693 [TBL] [Abstract][Full Text] [Related]
8. Development of Src tyrosine kinase substrate binding site inhibitors. Ye G; Tiwari R; Parang K Curr Opin Investig Drugs; 2008 Jun; 9(6):605-13. PubMed ID: 18516760 [TBL] [Abstract][Full Text] [Related]
9. Peptide-bond modification for metal coordination: peptides containing two hydroxamate groups. Ye Y; Liu M; Kao JL; Marshall GR Biopolymers; 2003; 71(4):489-515. PubMed ID: 14517900 [TBL] [Abstract][Full Text] [Related]
10. Characterization of the interactions between the active site of a protein tyrosine kinase and a divalent metal activator. Lin X; Ayrapetov MK; Sun G BMC Biochem; 2005 Nov; 6():25. PubMed ID: 16305747 [TBL] [Abstract][Full Text] [Related]
11. New syntheses of tetrazolylmethylphenylalanine and O-malonyltyrosine as pTyr mimetics for the design of STAT3 dimerization inhibitors. Dourlat J; Valentin B; Liu WQ; Garbay C Bioorg Med Chem Lett; 2007 Jul; 17(14):3943-6. PubMed ID: 17509878 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13. Noe MC; Natarajan V; Snow SL; Wolf-Gouveia LA; Mitchell PG; Lopresti-Morrow L; Reeves LM; Yocum SA; Otterness I; Bliven MA; Carty TJ; Barberia JT; Sweeney FJ; Liras JL; Vaughn M Bioorg Med Chem Lett; 2005 Jul; 15(14):3385-8. PubMed ID: 15953722 [TBL] [Abstract][Full Text] [Related]
13. SAR of carbon-linked, 2-substituted purines: synthesis and characterization of AP23451 as a novel bone-targeted inhibitor of Src tyrosine kinase with in vivo anti-resorptive activity. Shakespeare WC; Wang Y; Bohacek R; Keenan T; Sundaramoorthi R; Metcalf C; Dilauro A; Roeloffzen S; Liu S; Saltmarsh J; Paramanathan G; Dalgarno D; Narula S; Pradeepan S; van Schravendijk MR; Keats J; Ram M; Liou S; Adams S; Wardwell S; Bogus J; Iuliucci J; Weigele M; Xing L; Boyce B; Sawyer TK Chem Biol Drug Des; 2008 Feb; 71(2):97-105. PubMed ID: 18179464 [TBL] [Abstract][Full Text] [Related]
14. Naturally occurring homoisoflavonoids function as potent protein tyrosine kinase inhibitors by c-Src-based high-throughput screening. Lin LG; Xie H; Li HL; Tong LJ; Tang CP; Ke CQ; Liu QF; Lin LP; Geng MY; Jiang H; Zhao WM; Ding J; Ye Y J Med Chem; 2008 Aug; 51(15):4419-29. PubMed ID: 18610999 [TBL] [Abstract][Full Text] [Related]
15. Synthesis and evaluation of 3-phenylpyrazolo[3,4-d]pyrimidine-peptide conjugates as Src kinase inhibitors. Kumar A; Wang Y; Lin X; Sun G; Parang K ChemMedChem; 2007 Sep; 2(9):1346-60. PubMed ID: 17530729 [TBL] [Abstract][Full Text] [Related]
16. Carbonic anhydrase inhibitors: inhibition of cytosolic/tumor-associated isoforms I, II, and IX with iminodiacetic carboxylates/hydroxamates also incorporating benzenesulfonamide moieties. Santos MA; Marques S; Vullo D; Innocenti A; Scozzafava A; Supuran CT Bioorg Med Chem Lett; 2007 Mar; 17(6):1538-43. PubMed ID: 17251018 [TBL] [Abstract][Full Text] [Related]
17. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family. Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733 [TBL] [Abstract][Full Text] [Related]
18. Modeling the inhibition of peptide deformylase by hydroxamic acids: influence of the sulfur donor. Galardon E; Giorgi M; Artaud I Dalton Trans; 2007 Mar; (10):1047-52. PubMed ID: 17325780 [TBL] [Abstract][Full Text] [Related]
19. Metal-binding properties of a dicysteine-containing motif in protein tyrosine kinases. Ahmadibeni Y; Hanley M; White M; Ayrapetov M; Lin X; Sun G; Parang K Chembiochem; 2007 Sep; 8(13):1592-605. PubMed ID: 17674392 [TBL] [Abstract][Full Text] [Related]
20. Discovery of thienopyridines as Src-family selective Lck inhibitors. Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]